Regulating the function of myogenic transcription factors in cells and inhibiting DNA binding activity.9 With the continuous progression of MDFI research, MDFI was found to have significantly higher expression in pancreatic cancer, hepatocellular carcinoma, prostate cancer and ovarian cancer tissues than in adjacent normal tissues.10,11 In CRC, the MDFI promoter is highly methylated, which is a key event in tumorigenesis and progression.12 Wu T et al. confirmed that MDFI is closely related to drug action in breast cancer.13 However, the role of the MDFI in CRC has not been fully elucidated. Here, MDFI is linked to prostate carcinoma.